-
N288820-1gNicotinamideN-methyltransferase (NNMT) inhibitor: promotes myoblast differentiation.
-
N288820-250mgNicotinamideN-methyltransferase (NNMT) inhibitor: promotes myoblast differentiation.
-
N288820-25gNicotinamideN-methyltransferase (NNMT) inhibitor: promotes myoblast differentiation.
-
N288820-50mgNicotinamideN-methyltransferase (NNMT) inhibitor: promotes myoblast differentiation.
-
N288820-5gNicotinamideN-methyltransferase (NNMT) inhibitor: promotes myoblast differentiation.
-
N423920-1mlNicotinamideN-methyltransferase (NNMT) inhibitor: promotes myoblast differentiation.
-
-
N349290-1mgNonanoyl Coenzyme A-d17.
-
N288500-1mgNorleual, an angiotensin (Ang) IV analog, is a hepatocyte growth factor (HGF)/c-Met inhibitor with an IC50 of 3 pM. Norleual is an AT4 receptor antagonist and exhibits potent antiangiogenic activities.
-
N288500-2mgNorleual, an angiotensin (Ang) IV analog, is a hepatocyte growth factor (HGF)/c-Met inhibitor with an IC50 of 3 pM. Norleual is an AT4 receptor antagonist and exhibits potent antiangiogenic activities.
-
N288500-5mgNorleual, an angiotensin (Ang) IV analog, is a hepatocyte growth factor (HGF)/c-Met inhibitor with an IC50 of 3 pM. Norleual is an AT4 receptor antagonist and exhibits potent antiangiogenic activities.
-
N501217-1mlGeneral DescriptionNormal cynomolgus serum (NCYS) is tested for complement activity and certified to possess fully functional classical and alternative pathways of activation. NCYS was prepared from mixed gender cynomolgus monkeys. Each sample of